Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

Janney starts Interpace Biosciences at buy; fair value estimate $12

Janney Montgomery Scott launched coverage of Interpace Biosciences (NASDAQ:IDXG) with a “buy” rating and fair value estimate of $12. The stock closed at $4.81 on April 14. Analyst Paul Knight writes that Interpace has...

April 15, 2020

Executive Moves

TerrAscend appoints Jason Ackerman as permanent CEO; CFO to step down

Jason Ackerman TerrAscend (OTCQX:TRSSF) appointed Jason Ackerman as CEO and reported that its CFO, Adam Kozak, will step down as the company relocates its financial operations from Toronto to New York City. Mr. Ackerman...

April 14, 2020

Executive Moves

Five Prime Therapeutics appoints industry leader, Tom Civik, as CEO

Tom Civik Five Prime Therapeutics (NASDAQ:FPRX) appointed Tom Civik as president, CEO and a director. William Ringo, who served as Five Prime’s chairman and interim CEO since September 2019, will step down as CEO and...

April 14, 2020

Markets

Canaccord ups Vapotherm PT to $20 from $14

Canaccord Genuity raised its price target for Vapotherm (NYSE:VAPO) to $20 from $14, citing preannounced first quarter results that beat expectations. The stock closed at $16.65 on April 13. Vapotherm is focused on the...

April 14, 2020

Markets

Roth starts Stealth BioTherapeutics at buy; PT $9

Roth Capital Partners launched coverage of Stealth BioTherapeutics (NASDAQ:MITO) with a “buy” rating and $9 price target. The stock closed at $1.59 on April 13. Stealth is focused on developing drugs targeted for rare...

April 14, 2020

Markets

Brookline starts Bellerophon Therapeutics at buy; PT $35

Brookline Capital Markets initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and $35 price target. The stock closed at $11.91 on April 13. Bellerophon is developing inhaled nitric oxide...

April 14, 2020

Markets

HCW cuts Entasis Therapeutics PT to $5 from $18 on dilution

H.C. Wainwright slashed its price target for Entasis Therapeutics (NASDAQ:ETTX) to $5 from $18, but maintained its “buy” rating, citing a major financing that carries substantial dilution. The stock closed at $2.64 on...

April 14, 2020

Developments

Health Canada approves Spartan Bioscience rapid COVID-19 test

Health Canada approved Spartan Bioscience’s DNA analyzer, the Spartan Cube, as a rapid, accurate and portable COVID-19 test. Closely-held Spartan plans to immediately begin shipping the test to its federal and...

April 13, 2020

Developments

Bellerophon submits IND for INOpulse inhaled nitric oxide for COVID-19

Bellerophon Therapeutics (NASDAQ:BLPH) submitted an IND to the FDA to study INOpulse, a pulsed nitric oxide (NO) system, for the treatment of patients with COVID-19. The IND follows the FDA’s allowance of treatment with...

April 9, 2020

Markets

Cowen starts Stereotaxis at OP; PT $6

Cowen launched coverage of Stereotaxis (NYSE American:STXS) with an “outperform” rating and $6 price target. The stock closed at $2.71 on April 8. Genesis is Stereotaxis’ next-generation robotic magnetic navigation...

April 9, 2020

Markets

Analysts cuts Neuronetics PTs citing COVID-19 impact

Analysts for BTIG and Canaccord Genuity slashed their price target for Neuronetics (NASDAQ:STIM) but maintained their “buy” ratings, citing a potential leaner post-pandemic business model. Neuronetics markets the...

April 9, 2020

Markets

Stifel starts Cue Biopharma at buy; PT $21

Stifel initiated coverage of Cue Biopharma (NASDAQ:CUE) with a “buy” rating and $21 price target. The stock closed at $16.60, up $1.53, on April 8. “We believe the Immuno-STAT platform from which the company’ wholly...

April 9, 2020

Subscribe